Latest news with #MotasimSirhan
Fast Company
2 days ago
- Health
- Fast Company
A revolution in heart disease treatment
Cardiovascular disease affects 315 million people globally and is the world's leading cause of death. For the past quarter-century, it has been standard practice for heart surgeons to treat this by inserting small, mesh tubes called stents to widen or unblock patients' coronary arteries to restore blood flow. Unfortunately, many of those patients experienced additional issues—from blood clots to heart attacks—within years, sometimes months, of the procedure. That's where DynamX, a new vascular technology from Elixir Medical, comes in. Like traditional stents, DynamX is minimally invasive and expands arteries to promote blood flow, but their unique design also enables them to restore arteries' natural defense mechanisms, helping patients avoid life-threatening events or costly and dangerous repeat procedures. The technology's promise to allow cardiac patients to heal more completely and live full, productive lives earned Elixir a spot as one of Fast Company 's 2025 Most Innovative Companies. Novel technology, proven effectiveness Traditional stents solve heart patients' immediate, critical need for restoring arterial blood flow. However, because they don't heal the arteries themselves, about half of patients re-experience an adverse medical event within 10 years, says Motasim Sirhan, Elixir founder and CEO. DynamX is different. After six months, Elixir's implant transforms into an essential part of the artery itself as its mesh tube unlocks, freeing and reinforcing the artery's wall. The implant then gradually restores and adapts to the blood vessel's natural pulsing motion. 'You need to address the disease where it's originating, not the just symptoms of it,' Sirhan says. 'This is the first technology to do that.' In the spring and fall of 2024, Elixir announced the results of a pair of large, international randomized clinical trials that demonstrate DynamX's favorable results. Patients with these implants had 65% fewer serious heart events and 78% fewer issues in the left anterior descending artery—which is critical for heart function as it supplies 50% of blood to the heart—than patients with traditional stent implants. Last year, recognizing DynamX's promise, the U.S. Food and Drug Administration granted Elixir 'Breakthrough Device Designation' (BDD) on two applications of its DynamX technology: to treat heart artery blockage and serious artery blockages in the leg below the knee. BDD accelerates the review and approval process for novel technologies that may provide more effective treatment of life-threatening diseases and conditions. Patient-focused solutions As they developed DynamX, the company's researchers never lost sight of the seriousness and scale of the problem they were addressing. Many people begin to have cardiac issues in their 50s and 60s, requiring them to undergo multiple procedures. Patients often miss a substantial amount of work and sometimes can't participate fully in family activities. As Sirhan puts it, these hardships—on top of the millions or cardiac deaths annually—are 'not acceptable.' Elixir's innovative solution is the product of a multidisciplinary team of experts in physics, biology, chemistry, engineering, and other fields. The researchers addressed the challenge from different perspectives but with a singular mission: serving patients. 'What was important for us,' Sirhan says, 'was being able to make a difference in patient treatment and to not be fazed by the difficulty of the mission.'
Associated Press
18-03-2025
- Business
- Associated Press
Elixir Medical Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Elixir Medical is proud to have been named to Fast Company 's prestigious list of the World's Most Innovative Companies of 2025. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 609 organizations across 58 sectors and regions. 'Elixir is working to tackle the biggest problems in coronary and peripheral artery treatment by disrupting the status quo with its innovative technologies. In the U.S., one person dies every 33 seconds from cardiovascular disease, with coronary artery disease (CAD)—the most common form—being the leading cause of death globally. For patients who undergo percutaneous coronary intervention (PCI), the primary treatment for CAD, up to 20% experience repeat adverse events within five years due to stent failures, which we find unacceptable,' said Motasim Sirhan, CEO of Elixir Medical. Elixir's leading technology platform, the DynamX® bioadaptor, was designed to address the shortcomings of current PCI technologies such as drug-eluting stents and work toward a continued decrease in adverse event rates. By rethinking the way an implant could work adaptively with the body, Elixir developed the bioadaptor to have a unique mechanism of action that is designed to restore vessel motion and function without compromising the vessel's ability to heal naturally, intending to revolutionize patient care and set a new standard for coronary artery disease (CAD) treatment. Data from two randomized clinical trials studying the bioadaptor demonstrate that by enabling the coronary implant to adapt to the vessel, artery hemodynamic modulation is restored, and PCI treatment outcomes can be further improved. Elixir received two FDA Breakthrough Device Designations in 2024 for the DynamX® Sirolimus-Eluting Coronary Bioadaptor System for CAD treatment and the DynamX® BTK System for peripheral use to treat chronic limb-threatening ischemia. Elixir Medical is also working on LithiX Hertz Contact Intravascular Lithotripsy (IVL) System for calcium fragmentation in moderate to severe calcified coronary artery lesions during PCI procedure. Calcified lesions are associated with limited vessel expansion and contribute to increased adverse outcomes. Compared to other technologies for calcium modification, the LithiX Hertz Contact IVL System mechanism of action is based on the physics principle of Hertz Contact Stress and requires no energy source or capital equipment, positively impacting procedure workflow with short procedure times and a simpler learning curve, while delivering excellent clinical results. The World's Most Innovative Companies stands as Fast Company 's hallmark franchise and one of its most anticipated editorial efforts of the year. To determine honorees, Fast Company' s editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world. 'Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future,' said Fast Company editor-in-chief Brendan Vaughan. 'This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward.' The full list of Fast Company's Most Innovative Companies honorees can now be found at It will also be available on newsstands beginning March 25. Fast Company will host the Most Innovative Companies Summit and Gala for honorees on June 5. The summit features a day of inspiring content, followed by a creative black-tie gala including networking, a seated dinner, and an honoree presentation. ABOUT ELIXIR MEDICAL Elixir Medical Corporation, a privately held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. Our transformative technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Visit us at and on LinkedIn and X. The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device. Limited by Federal (or United States) law to investigational use. The LithiX IVL System is not approved for sale in the U.S. ABOUT FAST COMPANY Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with fellow business publication Inc. For more information, please visit . CONTACT: Richard Laermer RLM PR (212) 741-5106 X 216 SOURCE: Elixir Medical Copyright Business Wire 2025. PUB: 03/18/2025 10:47 AM/DISC: 03/18/2025 10:47 AM
